Abstract: Provided herein is a composition, comprising: a plurality of nanoentities comprising an inner core surrounded by an outer shell, the outer shell comprising a polymer, the inner core comprising at least one hydrophobic compound, wherein the nanoentities comprise a pharmaceutical agent, wherein the pharmaceutical agent is an antibody or a fragment thereof, wherein the antibody or the fragment thereof binds to an epitope of an activated mutated KRAS protein. These anti-KRAS antibodies formulated into particular nanoentities are able to be intracellular delivered and further, are able to perform their biological activity inside the cell, thus being useful in the treatment of cancer and other disease associated with a mutation in a KRAS gene.

Abstract: The present invention generally relates to particles, including nanocapsules or other nanoentities, comprising a polymer such as polysialic acid. The particles are able to access the interior of the cells, and/or to procure the intracellular release of the associated drugs. In 5 one aspect, the present invention is directed to nanocapsules or other entities having an exterior or surface comprising a polymer such as polysialic acid. In some cases, targeting moieties such as Lyp-1 or tLyp-1 peptide are bonded to the polymer, e.g., using aminoalkyl (C1-C4) succinimide or other linkers. These may be created, for example, by reacting a carboxylate moiety on a polymer with an aminoalkyl maleimide (C1-C4) or an aminoalkyl 10 (C1-C4) methacrylamide, and reacting the resulting aminoalkyl (C1-C4) maleimide or the aminoalkyl (C1-C4) methacrylamide to a cysteine or other sulfur group.

Abstract: The present invention generally relates to particles, including nanocapsules or other nanoentities, comprising a polymer such as polysialic acid. The particles are able to access the interior of the cells, and/or to procure the intracellular release of the associated drugs. In 5 one aspect, the present invention is directed to nanocapsules or other entities having an exterior or surface comprising a polymer such as polysialic acid. In some cases, targeting moieties such as Lyp-1 or tLyp-1 peptide are bonded to the polymer, e.g., using aminoalkyl (C1-C4) succinimide or other linkers. These may be created, for example, by reacting a carboxylate moiety on a polymer with an aminoalkyl maleimide (C1-C4) or an aminoalkyl 10 (C1-C4) methacrylamide, and reacting the resulting aminoalkyl (C1-C4) maleimide or the aminoalkyl (C1-C4) methacrylamide to a cysteine or other sulfur group.

Abstract: The present invention relates to the design and development of nanocapsule systems for the administration of active substances, wherein the nanocapsules of the system have a mean diameter less than 1 ?m and are characterized by comprising (a) a protamine shell, (b) an oily core, and one or more surfactants characterized by having a hydrophilic-lipophilic ratio greater than 8, provided that said surfactant is not a phospholipid.

Abstract: The invention relates to a system for administering active ingredients, including nanocapsules comprising an oil, a cationic surfactant and a polymer selected from the group consisting of polyglutamic acid (PGA), polyglutamic-polyethyleneglycol acid (PGA-PEG), hyaluronic acid (HA) and polyasparagine (PAsn) or a combination of same and, optionally, an active ingredient, with the condition that when the polymer includes polyglutamic acid or polyglutamic-polyethyleneglycol acid (PGA-PEG) the active ingredient is not a didemnin or a tamandarin. The invention also relates to methods for obtaining said nanocapsule system, the pharmaceutical compositions thereof and the use of same in medicine.

Abstract: The present invention relates to the design and development of nanocapsule systems for the administration of active substances, wherein the nanocapsules of the system have a mean diameter less than 1 ?m and are characterized by comprising (a) a protamine shell, (b) an oily core, and one or more surfactants characterized by having a hydrophilic-lipophilic ratio greater than 8, provided that said surfactant is not a phospholipid.

Abstract: The invention relates to a system for administering active ingredients, including nanocapsules comprising an oil, a cationic surfactant and a polymer selected from the group consisting of polyglutamic acid (PGA), polyglutamic-polyethyleneglycol acid (PGA-PEG), hyaluronic acid (HA) and polyasparagine (PAsn) or a combination of same and, optionally, an active ingredient, with the condition that when the polymer includes polyglutamic acid or polyglutamic-polyethyleneglycol acid (PGA-PEG) the active ingredient is not a didemnin or a tamandarin. The invention also relates to methods for obtaining said nanocapsule system, the pharmaceutical compositions thereof and the use of same in medicine.

Abstract: Application of nanoparticles based on hydrophilic polymers as pharmaceutical forms for the administration of active macromolecules. The nanoparticles (having a nanometric size and a hydrophilic character), also called nanospheres or latex, are colloidal systems comprised of the combination of hydrophilic polymers and an active ingredient having a high molecular weight (active macromolecule, molecular weight higher than 1000 daltons). The hydrophilic polymers are the chitosan (an aminopolysaccharide) or its derivatives and polyoxyethylene or its derivatives. The association of the active macromolecule to said nanoparticles takes place in an aqueous phase without having to use organic solvents or auxiliary toxic substances. The active ingredient charge capacity of the nanoparticles is extremely high and additionally said charge is released in a controlled and time extended way. Additionally, said nanoparticles have a positive surface electric charge whose intensity may vary in relation to its composition.

Abstract: Stabilization of colloidal systems through the formation of lipid-polyssacharide complexes. Development of a procedure for the preparation of colloidal systems involving a combination of two ingredients: a water soluble and positively charged polyssacharide and a negatively charged phospholipid. Colloidal systems (submicron emulsions and polymeric nanoparticles and nanocapsules) are stabilized through the formation, at the interface, of an ionic complex: aminopolyssachride-phospholipid. These colloidal systems are characterized by their positive charge and their improved stability. Furthermore, they can be freeze-dried, stored in a dry state and hydrated when required. They can be interesting systems for the administration of drugs by the oral, transdermal, ocular, nasal and vaginal routes of administration. In addition, they can be of interest for cosmetic use.